Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer.

Luhn P, Chui SY, Hsieh AF, Yi J, Mecke A, Bajaj PS, Hasnain W, Falgas A, Ton TG, Kurian AW.

J Comp Eff Res. 2019 Aug 9. doi: 10.2217/cer-2019-0077. [Epub ahead of print]

PMID:
31394922
2.

A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.

Falgàs A, Pallarès V, Unzueta U, Céspedes MV, Arroyo-Solera I, Moreno MJ, Gallardo A, Mangues MA, Sierra J, Villaverde A, Vázquez E, Mangues R, Casanova I.

Haematologica. 2019 Jun 27. pii: haematol.2018.211490. doi: 10.3324/haematol.2018.211490. [Epub ahead of print]

3.

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia.

Pallarès V, Hoyos M, Chillón MC, Barragán E, Prieto Conde MI, Llop M, Falgàs A, Céspedes MV, Montesinos P, Nomdedeu JF, Brunet S, Sanz MÁ, González-Díaz M, Sierra J, Mangues R, Casanova I.

Cancers (Basel). 2018 Nov 13;10(11). pii: E436. doi: 10.3390/cancers10110436.

4.

CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis.

Moreno MJ, Gallardo A, Novelli S, Mozos A, Aragó M, Pavón MÁ, Céspedes MV, Pallarès V, Falgàs A, Alcoceba M, Blanco O, Gonzalez-Díaz M, Sierra J, Mangues R, Casanova I.

PLoS One. 2018 Jun 19;13(6):e0198789. doi: 10.1371/journal.pone.0198789. eCollection 2018.

5.

Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin.

Díaz R, Pallarès V, Cano-Garrido O, Serna N, Sánchez-García L, Falgàs A, Pesarrodona M, Unzueta U, Sánchez-Chardi A, Sánchez JM, Casanova I, Vázquez E, Mangues R, Villaverde A.

Small. 2018 Jun;14(26):e1800665. doi: 10.1002/smll.201800665. Epub 2018 May 29.

PMID:
29845742

Supplemental Content

Loading ...
Support Center